drugset / Trial / NCT07275788
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Phase 1
Recruiting
15 enrolled
Regend Therapeutics
Shanghai Tongji Hospital, Tongji University School of Medicine · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
Timeline
- Start
- 2026-01-08
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGEND003 | Cell therapy | — | — |